Protea Biosciences Group, Inc. 4
4 · Protea Biosciences Group, Inc. · Filed Mar 27, 2015
Insider Transaction Report
Form 4
ANTOLINE STEVE
Director10% Owner
Transactions
- Other
Warrant (right to buy)
2015-03-20+1,100,523→ 1,100,523 total(indirect: See Footnote)Exercise: $0.50From: 2015-03-20Exp: 2020-03-20→ Common Stock (1,100,523 underlying) - Other
Common Stock
2015-03-20+2,201,046→ 14,885,481 total(indirect: See Footnote)
Footnotes (2)
- [F1]On March 20, 2015, the Issuer's Board of Directors authorized the conversion of an aggregate of $$341,084.81 principal amount of, and $192,784.63 of accrued interest on promissory notes issued by the Issuer to Summit Resources, Inc. ("Summit"), and $16,392.14 of accounts payable by the Issuer to Summit, into 2,201,046 units of securities, each unit consisting of one share of the Issuer's common stock and a five-year warrant to purchase one-half share of Common Stock, at an exercise price of $0.50 per whole share, at a conversion price of $0.25 per unit. None of these obligations was convertible by its terms.
- [F2]Represents the shares of Common Stock owned of record by Summit. Steve Antoline has voting and dispositive control over any securities owned of record by Summit and may be deemed to beneficially own the shares of common stock held of record by Summit.